Moreover, Wang et al. developed a DC vaccine against personalized TAAs to treat patients with glioblastoma multiforme (GBM) or advanced lung cancer in combination with low-dose cyclophosphamide, polyinosinic–polycytidylic acid (poly I:C), imiquimod, and an anti-PD-1 antibody (NCT02808364). The gene discussed is PDCD1; the disease is glioblastoma.